Plant-derived drugs and their applicaction in the anticancer therapy

1. Balunas M. J., Kinghorn A. D. Drug discovery from medicinal plants. Life Sci. 2005; 78, 431–441.

2. Koehn F. E., Carter G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005; 4, 206–220.

3. Lahlou M. The success of natural products in drug Discovery. Pharmacol. Pharm. 2013; 4, 17–31.

4. Newman D. J., Cragg G. M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016; 79, 629–661.

5. Hartwell J. L. Plants used against cancer: A survey (Bioactive Plants, Vol. 2). Michigan: Quarterman Publications Inc. 1984.

6. Cragg G. M., Newman D. J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005; 100, 72–79.

7. Cibikova P., Sturdikova M., Maruna M. Natural compounds of plant origin and their application in therapy of oncological diseases. Chem. Listy 2010; 104, 12–20.

8. Singh S., Sharma B., Kanwar S. S., Kumar A. Lead phytochemicals for anticancer drug development. Front. Plant. Sci. 2016; 7, 1667.

9. Pan L., Chai H. Y., Kinghorn A. D. The continuing search for antitumor agents from higher plants. Phytochem. Lett. 2010; 3, 1–8.

10. Drugs.com. ELDISINE POWDER FOR SOLUTION FOR INJECTION 5.0 MG. https://www.drugs.com/uk/eldisine-powder-for-solution-for-injection-5-0-mg-leaflet.html (15.01.2019).

11. Gregory R. K., Smith I. E. Vinorelbine – a clinical review. Brit. J. Cancer 2000; 82, 1907–1913.

12. Gerullis H., Wawroschek F., Kohne C. H., Ecke T. H. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther. Adv. Urol. 2017; 9, 28–35.

13. Hearn B. R., Shaw S. J., Myles D. C. Microtubule targeting agents. In: Taylor J. B., Triggle D. J. (eds.) Comprehensive Medicinal Chemistry II. Amsterdam: Elsevier Science 2007.

14. Yousefzadi M., Sharifi M., Behmanesh M., Moyano E., Bonfill M., Cusido R. M., Palazon J. Podophyllotoxin: Current approaches to its biotechnological production and future challenges. Eng. Life Sci. 2010; 10, 281–292.

15. Liu Y. Q., Tian J., Qian K., Zhao X. B., Morris-Natschke S. L., Yang L., Nan X., Tian X., Lee K.-H. Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents. Med. Res. Rev. 2015; 35, 1–62.

16. Ojima I., Lichtenthal B., Lee S., Wang C. W., Wang X. Taxane anticancer agents: a patent perspective. Expert Opin. Ther. Pat. 2016; 26, 1–20.

17. Coronel J., Cetina L., Candelaria M., Gonzalez-Fierro A., Arias D., Cantu D., Dueñas-González A. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med. Oncol. 2009; 26, 210–214.

18. Chan B. A., Coward J. I. G. Chemotherapy advances in small-cell lung cancer. J. Thorac. Dis. 2013; 5, S565–S578.

19. BioNumerik Pharmaceuticals. Karenitecin versus topotecan in patients with advanced epithelial ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT00477282 (15. 01. 2019).

20. Rajan R., Varghese S. C., Kurup R., Gopalakrishnan R., Venkataraman R., Satheeshkumar K., Baby S. HPTLC-based quantification of camptothecin in Ophiorrhiza species of the southern Western Ghats in India. Cogent. Chemistry 2016; 2, 1275408.

21. Lu S. Q., Wang J. M. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J. Hematol. Oncol. 2014; 7, 2.

22. Nazha A., Kantarjian H., Cortes J., Quintas-Cardama A. Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia. Expert Opin. Pharmacol. 2013; 14, 1977–1986.

23. Khazir J., Mir B. A., Pilcher L., Riley D. L. Role of plants in anticancer drug discovery. Phytochem. Lett. 2014; 7, 173–181.

24. Alchin D. R. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol. Ther. (Heidelb.) 2014; 4, 157–164.

25. Case Comprehensive Cancer Center. Combretastatin A4 phosphate in treating patients with advanced anaplastic thyroid cancer. https://clinicaltrials.gov/ct2/show/NCT00060242?term=combretastatin-A4-phosphate&rank=5 (15. 01. 2019).

26. Garon E. B., Neidhart J. D., Gabrail N. Y., de Oliveira M. R., Balkissoon J., Kabbinavar F. A randomized Phase II trial of the tumor vascular disrupting agent CACA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Oncotargets Ther. 2016; 9, 7275–7283.

27. Chase D. M., Chaplin D. J., Monk B. J. The development and use of vascular targeted therapy in ovarian cancer. Gynecol. Oncol. 2017; 145, 393–406.

28. Madlambayan G. J., Meacham A. M., Hosaka K., Mir S., Jorgensen M., Scott E. W., Siemann W., Cogle C. R. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010; 116, 1539–1547.

29. Li J. Z., Ke Y. B., Misra H. P., Trush M. A., Li Y. R., Zhu H., Jia Z. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent. Toxicol. Appl. Pharmacol. 2014; 281, 285–293.

30. Bey E. A., Bentle M. S., Reinicke K. E., Dong Y., Yang C. R., Girard L., Minna J. D., Bornmann W. G., Gao J., Boothman D. A. An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. PNAS 2007; 104, 11832–11837.

31. Sun Y. Y., Xun K. L., Wang Y. T., Chen X. P. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anti-Cancer Drug 2009; 20, 757–769.

32. Liu C. H., Tang W. C., Sia P., Huang C. C., Yang P. M., Wu M. H., Lai I. L., Lee K. H. berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT) – Associated Genes with Predictive and Prognostic Relevance. Int. J. Med. Sci. 2015; 12, 63–71.

33. Chu S. C., Yu C. C., Hsu L. S., Chen K. S., Su M. Y., Chen P. N. Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor –induced angiogenesis in human cervical cancer cells. Mol. Pharmacol. 2014; 86, 609–623.

34. Bao J. L., Huang B. R., Zou L. D., Chen S. H., Zhang C., Zhang Y. L., Chen M., Wan J.-B., Su H., Wang Y., He C. Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents. PLOS One 2015; 10, e0139298.

35. Liu Q., Jiang H. Y., Liu Z. J., Wang Y., Zhao M. N., Hao C. Y., Feng S., Guo H., Xu B., Yang Q., Gong Y., Shao C. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLOS One. 2011; 6, e23427.

36. Najmi S., Korah R., Chandra R., Abdellatif M., Wieder R. Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin. Cancer Res. 2005; 11, 2038–2046.

37. Kelland L. R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert. Opin. Inv. Drug 2000; 9, 2903–2911.

38. Wang L. M., Ren D. M. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini-Rev. Med. Chem. 2010; 10, 1058–1070.

39. Hirose K., Imaeda N., Tokudome Y., Goto C., Wakai K., Matsuo K., Ito H., Toyama T., Iwata H., Tokudome S., Tajima K. Soybean products and reduction of breast cancer risk: a case control study in Japan. Brit. J. Cancer 2005; 93, 15–22.

40. Perabo F. G. E., Von Low E. C., Ellinger J., Von Rucker A., Muller S. C., Bastian P. J. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11, 6–12.

41. Sarkar F. H., Li Y. W. The role of isoflavones in cancer chemoprevention. Front. Biosci.-Landmrk. 2004; 9, 2714–2724.

42. Schnekenburger M., Diederich M. Nutritional epigenetic regulators in the field of cancer: new avenues for chemopreventive approaches. In: Gray S. G. (ed.) Epigenetic Cancer Therapy. London: Academic Press 2015.

43. Spagnuolo C., Russo G. L., Orhan I. E., Habtemariam S., Daglia M., Sureda A., Nabavi S. F., Devi K. P., Loizzo M. R., Tundis R., Nabavi S. M. Genistein and cancer: current status, challenges, and future directions. Adv. Nutr. 2015; 6, 408–419.

44. Mishra B. B., Tiwari V. K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem. 2011; 46, 4769–807.

45. Pyne N. J., Tonelli F., Lim K. G., Long J. S., Edwards J., Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem. Soc. Trans. 2012; 40, 94–100.

46. Gamble J. R., Xia P., Hahn C. N., Drew J. J., Drogemuller C. J., Brown D., Vadas M. A. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int. J. Cancer 2006; 118, 2412–2420.

47. Georgaki S., Skopeliti M., Tsiatas M., Nicolaou K. A., Ioannou K., Husband A., Bamias A., Dimopoulos M. A., Constantinou A. I., Tsitsilonis O. E. Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. J. Cell. Mol. Med. 2009; 13, 3929–3938.

48. Fotopoulou C., Vergote I., Mainwaring P., Bidzinski M., Vermorken J. B., Ghamande S. A., Harnett P., Del Prete S. A., Green J. A., Spaczynski M., Blagden S., Gore M., Ledermann J., Kaye S., Gabra H. Weekly AUC2 carboplatin in acquired platinum resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase Ill OVATURE multicenter randomized study. Ann. Oncol. 2014; 25, 160–165.

49. Xiong J., Li J. S., Yang Q., Wang J., Su T. F., Zhou S. Gossypol has anti-cancer effects by dual targeting MDM2 and VEGF in human breast cancer. Breast Cancer Res. 2017; 19, 27.

50. Meng Y., Tang W. H., Dai Y., Wu X. Q., Liu M. L., Ji Q., Ji M., Pienta K., Lawrence T., Xu L. Natural BH3 mimetic (–)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol. Cancer Ther. 2008; 7, 2192–2202.

51. Bimonte S., Barbieri A., Leongito M., Piccirillo M., Giudice A., Pivonello C., de Angelis C., Granata V., Palaia R., Izzo F. Curcumin anticancer studies in pancreatic cancer. Nutrients 2016; 8, E433